Zehra Gundogan

Sustained Benefits of Zuranolone in Patients With Major Depressive Disorder: Results From the LANDSCAPE Clinical Development Program

Abstract: Introduction Many patients with major depressive disorder (MDD) experience relapse after responding to standard-of-care antidepressants. Zuranolone is a neuroactive steroid and ...

Zehra Gundogan ;

Manny Garcia ;

01/19/2023

Safety, Tolerability, and Efficacy of Zuranolone Repeat Treatment Courses in Adult Patients With Major Depressive Disorder–An Analysis of the Open-Label, Phase 3 SHORELINE Study

Abstract: Introduction Rapid response and episodic treatment potential are important in the treatment of major depressive disorder (MDD). Zuranolone is a neuroactive steroid and positive ...

Ramon Iovine ;

Zehra Gundogan ;

01/19/2023

Safety and Efficacy of Zuranolone in Young Adults With Major Depressive Disorder: A Subgroup Analysis of the Open-Label, Long-Term, Phase 3 SHORELINE Study

Abstract: Introduction There is a greater prevalence of major depressive disorder (MDD) in young adults compared with older adults. Zuranolone is a neuroactive steroid and positive allost...

Zehra Gundogan ;

Ryan Brown , MD;

01/19/2023

Efficacy and Safety of Zuranolone in Adults With Major Depressive Disorder With and Without Use of Standard-of-Care Antidepressants at Baseline in the LANDSCAPE Clinical Development Program

Abstract: Introduction Zuranolone is a neuroactive steroid and positive allosteric modulator of synaptic and extrasynaptic GABAA receptors in clinical development as an oral, once-daily, ...

Coleville Brown ;

Zehra Gundogan ;

01/19/2023